FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048887321> ?p ?o ?g. }

• W3048887321 endingPage "8124" @default.
• W3048887321 startingPage "8109" @default.
• W3048887321 abstract "Conventional immunotherapy for glioma is not only expensive but also demonstrates less-than-desired clinical efficacy. In this study, we evaluated the immunotherapeutic efficacy of a tumor cell lysate-based hybrid glioma vaccine developed using a molecular-based approach.First, the ability of the autologous (9L-cell lysate) and allogeneic (C6-cell lysate) vaccines against glioma, individually and in combination, to activate Fischer344 rat dendritic cells (DCs) was determined. Next, the activated DCs were co-cultured with T lymphocytes and screened for the optimal DC-to-T-cell ratio. The in vitro efficacy of the DC/T-cell vaccine formulations subjected to different immunogen treatments and co-cultured with glioma cells was evaluated based on glioma cell viability and monocyte chemoattractant protein (MCP)-2 and interferon (IFN)-γ secretion. Subsequently, the efficacy of the 9L + C6 hybrid vaccine was evaluated in 32 glioma rat models, randomly allocated to the following five treatment groups: blank control, tumor, vaccine treatment, thymosin treatment, and vaccine + thymosin treatment (combined treatment). Changes in survival duration, intracranial tumor volume, peripheral blood immune-cell (CD4+ T, CD8+ T, and natural killer [NK] cell) count, and serum cytokine (interleukin [IL]-2, IL-10) levels were assessed in these groups.The hybrid vaccine demonstrated the highest glioma cell apoptosis and the lowest cell viability and promoted MCP-2 and IFN-γ secretion in vitro. The vaccine treatment and combined treatment groups demonstrated longer survival duration, lower intracranial tumor volume, and higher immune cell glioma tissue infiltration and IL-2 secretion than the untreated tumor group, indicating the vaccine's good in vivo efficacy. Thymosin treatment had minimal effect in enhancing anti-glioma immunity.We demonstrated the feasibility of combining autologous and allogeneic tumor cell lysates to stimulate specific host cell immune response against glioma cells. The good clinical efficacy of our developed glioma hybrid vaccine in rat models suggests its potential clinical application." @default.
• W3048887321 created "2020-08-18" @default.
• W3048887321 creator A5002542586 @default.
• W3048887321 creator A5023000950 @default.
• W3048887321 creator A5041473205 @default.
• W3048887321 creator A5056076367 @default.
• W3048887321 creator A5064887605 @default.
• W3048887321 creator A5087809584 @default.
• W3048887321 date "2020-08-01" @default.
• W3048887321 modified "2023-10-18" @default.
• W3048887321 title "<p>A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model</p>" @default.
• W3048887321 cites W1509288539 @default.
• W3048887321 cites W1985033543 @default.
• W3048887321 cites W1986677262 @default.
• W3048887321 cites W2034807686 @default.
• W3048887321 cites W2071327437 @default.
• W3048887321 cites W2122225729 @default.
• W3048887321 cites W2149387197 @default.
• W3048887321 cites W2156480430 @default.
• W3048887321 cites W2163838780 @default.
• W3048887321 cites W2168028214 @default.
• W3048887321 cites W2336209861 @default.
• W3048887321 cites W2343269734 @default.
• W3048887321 cites W2404653413 @default.
• W3048887321 cites W2465860350 @default.
• W3048887321 cites W2472029252 @default.
• W3048887321 cites W2506616866 @default.
• W3048887321 cites W2520382278 @default.
• W3048887321 cites W2533941196 @default.
• W3048887321 cites W2556033701 @default.
• W3048887321 cites W2558219863 @default.
• W3048887321 cites W2584466409 @default.
• W3048887321 cites W2594259396 @default.
• W3048887321 cites W2605630275 @default.
• W3048887321 cites W2728953905 @default.
• W3048887321 cites W2769936894 @default.
• W3048887321 cites W2770221757 @default.
• W3048887321 cites W2783151941 @default.
• W3048887321 cites W2783799918 @default.
• W3048887321 cites W2808189115 @default.
• W3048887321 cites W2883582676 @default.
• W3048887321 cites W2895357007 @default.
• W3048887321 cites W2896149666 @default.
• W3048887321 cites W2901887176 @default.
• W3048887321 cites W2903067379 @default.
• W3048887321 cites W2914528646 @default.
• W3048887321 cites W2937056531 @default.
• W3048887321 cites W2941644628 @default.
• W3048887321 cites W2989957419 @default.
• W3048887321 cites W804995307 @default.
• W3048887321 cites W979102926 @default.
• W3048887321 doi "https://doi.org/10.2147/ott.s259516" @default.
• W3048887321 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7438187" @default.
• W3048887321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32884294" @default.
• W3048887321 hasPublicationYear "2020" @default.
• W3048887321 type Work @default.
• W3048887321 sameAs 3048887321 @default.
• W3048887321 citedByCount "4" @default.
• W3048887321 countsByYear W30488873212021 @default.
• W3048887321 countsByYear W30488873212022 @default.
• W3048887321 crossrefType "journal-article" @default.
• W3048887321 hasAuthorship W3048887321A5002542586 @default.
• W3048887321 hasAuthorship W3048887321A5023000950 @default.
• W3048887321 hasAuthorship W3048887321A5041473205 @default.
• W3048887321 hasAuthorship W3048887321A5056076367 @default.
• W3048887321 hasAuthorship W3048887321A5064887605 @default.
• W3048887321 hasAuthorship W3048887321A5087809584 @default.
• W3048887321 hasBestOaLocation W30488873211 @default.
• W3048887321 hasConcept C167672396 @default.
• W3048887321 hasConcept C203014093 @default.
• W3048887321 hasConcept C2777701055 @default.
• W3048887321 hasConcept C2778227246 @default.
• W3048887321 hasConcept C502942594 @default.
• W3048887321 hasConcept C71924100 @default.
• W3048887321 hasConcept C8891405 @default.
• W3048887321 hasConceptScore W3048887321C167672396 @default.
• W3048887321 hasConceptScore W3048887321C203014093 @default.
• W3048887321 hasConceptScore W3048887321C2777701055 @default.
• W3048887321 hasConceptScore W3048887321C2778227246 @default.
• W3048887321 hasConceptScore W3048887321C502942594 @default.
• W3048887321 hasConceptScore W3048887321C71924100 @default.
• W3048887321 hasConceptScore W3048887321C8891405 @default.
• W3048887321 hasLocation W30488873211 @default.
• W3048887321 hasLocation W30488873212 @default.
• W3048887321 hasLocation W30488873213 @default.
• W3048887321 hasOpenAccess W3048887321 @default.
• W3048887321 hasPrimaryLocation W30488873211 @default.
• W3048887321 hasRelatedWork W110876028 @default.
• W3048887321 hasRelatedWork W1996150995 @default.
• W3048887321 hasRelatedWork W2350488082 @default.
• W3048887321 hasRelatedWork W2387430262 @default.
• W3048887321 hasRelatedWork W3031847554 @default.
• W3048887321 hasRelatedWork W3167775801 @default.
• W3048887321 hasRelatedWork W4206180740 @default.
• W3048887321 hasRelatedWork W4210825082 @default.
• W3048887321 hasRelatedWork W4223934326 @default.
• W3048887321 hasRelatedWork W4385616388 @default.
• W3048887321 hasVolume "Volume 13" @default.

• next